Mirion Technologies, Inc. (MIR) SEC Filings & Earnings Calls
EquiReason read 16 Mirion Technologies, Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-08-31 — Board approved new $250M share repurchase program through 2031; completed prior $100M program with $40M repurchases in Q3 2026..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 3.7B
- P/E TTM
- 148.1
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
31 Aug 20268-K · 8.01Board approved new $250M share repurchase program through 2031; completed prior $100M program with $40M repurchases in Q3 2026.open
Figures in the filing · each found in the filing text
| share repurchase amount · Q3-2026 | $40M |
Risks flagged
Share repurchase program may be suspended or terminated at any time; depends on market conditions, debt agreements, and alternative investments.
“The Company cannot predict when or if, or at what prices, it will repurchase any shares... the 2026 Repurchase Program may be suspended or terminated at any time by the Company without prior notice.” · word for word
29 Jul 202610-QMirion reported Q2 2026 revenue of $266.8M, up 20% YoY, with strong Nuclear & Safety growth and improved margins; Adjusted EBITDA up 28%.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $267M | +20% y/y |
| Net income attributable to Mirion Technologies, Inc. · Q2-2026 | $8M | -7% y/y |
| Adjusted EBITDA · Q2-2026 | $65M | +28% y/y |
| Backlog · 2026-06-30 | $1.14B | +3% y/y |
| Nuclear & Safety Revenue · Nuclear & Safety · Q2-2026 | $186M | +31% y/y |
| Medical Revenue · Medical · Q2-2026 | $81M | -1% y/y |
| Nuclear & Safety Income from Operations · Nuclear & Safety · Q2-2026 | $26M | +37% y/y |
| Medical Income from Operations · Medical · Q2-2026 | $15M | +36% y/y |
| Gross Profit · Q2-2026 | $133M | +30% y/y |
| Operating Cash Flow · H1-2026 | $77M | +61% y/y |
Risks flagged
China Tariff and Localization Risk
“China continues to expand localization requirements that could require us to localize manufacturing or source local components, or to otherwise modify our business operations.” · word for word
Russia/China Sanctions Exposure
“The remaining performance obligations in our backlog for Russian- and Chinese-related projects were approximately $124.0 million at June 30, 2026.” · word for word
Fixed-Price Contract Risk
“Fixed-price contracts carry inherent risks, including risks of losses from underestimating costs, operational difficulties and other changes that may occur over the contract period.” · word for word
28 Jul 20268-K · 2.02Revenues $267M (+20% y/y); GAAP Net Income $8M (-5% y/y); Adjusted EBITDA $65M (+28% y/y); Guidance: Revenue growth 22-24%, organic 5-7%, adjusted EBITDA $285-300M (margin 25-26%), adjusted free cash flow $155-175M, adjusted EPS $0.48-0.55earningsopen
Figures in the filing · each found in the filing text
| Revenues · consolidated · Q2-2026 | $267M | +20% y/y |
| GAAP Net Income · consolidated · Q2-2026 | $8M | -5% y/y |
| Adjusted EBITDA · consolidated · Q2-2026 | $65M | +28% y/y |
| GAAP Diluted EPS · consolidated · Q2-2026 | $0.03 | -25% y/y |
| Adjusted EPS · consolidated · Q2-2026 | $0.12 | +9% y/y |
| Orders (ex-acquisitions) · consolidated · Q2-2026 | $229M | +10% y/y |
| Orders (including acquisitions) · consolidated · Q2-2026 | $291M | +40% y/y |
Guidance
Revenue growth 22-24%, organic 5-7%, adjusted EBITDA $285-300M (margin 25-26%), adjusted free cash flow $155-175M, adjusted EPS $0.48-0.55
Reaffirmed all FY2026 guidance. Management cites margin expansion, orders and backlog growth, and nuclear power opportunities. Well-positioned for H2 accelerated revenue growth.
Risks flagged
GAAP net income decline despite revenue growth
“GAAP net income was $8.1 million, a 4.7% decrease compared to $8.5 million” · word for word
Dependence on acquisitions for growth
“Orders including acquisitions +40% vs organic +10%”
29 Apr 202610-QTotal revenues $258M (+28% y/y); Net loss $-3M; Adjusted EBITDA $54M (+16% y/y); Guidance: No formal guidance providedopen
Figures in the filing · each found in the filing text
| Total revenues · Q1-2026 | $258M | +28% y/y |
| Net loss · Q1-2026 | $-3M | |
| Adjusted EBITDA · Q1-2026 | $54M | +16% y/y |
| Remaining performance obligations · 2026-03-31 | $1.12B | |
| Cash and cash equivalents · 2026-03-31 | $398M | |
| Nuclear & Safety revenue · Nuclear & Safety · Q1-2026 | $186M | +39% y/y |
| Medical revenue · Medical · Q1-2026 | $72M | +5% y/y |
| Operating cash flow · Q1-2026 | $19M | -47% y/y |
Guidance
No formal guidance provided
Strong backlog growth, nuclear megatrends, and recent acquisitions position the company for growth, but margin pressure from acquisition-related costs and geopolitical risks remain.
Risks flagged
Geopolitical and Trade Risk
“Additional tariffs and trade restrictions may result in increased manufacturing costs and product pricing, further supply chain disruptions, limit access to end markets and lower profitability.” · word for word
Russia Exposure
“As of March 31, 2026, the Company has approximately $8.7 million in net contract assets and accounts receivable for Russian customers and channel partners. The remaining performance obligations in our backlog for Russian-related projects were approximately $98.4 million at March 31, 2026.” · word for word
Integration Risk from Acquisitions
“A large driver of our historical growth has been the acquisition and integration of related businesses. Our ability to integrate, restructure, and leverage synergies of these businesses will impact our operating results over time.” · word for word
28 Apr 20268-K · 2.02Mirion reports Q1 2026 revenue up 27.5% to $257.6M, orders up 42% including acquisitions, reaffirms most guidance, revises adjusted EPS down slightly due to CEO grant.earningsopen
Figures in the filing · each found in the filing text
| Revenues · Q1-2026 | $258M | +28% y/y |
| GAAP net loss · Q1-2026 | $-3M | -950% y/y |
| Adjusted EBITDA · Q1-2026 | $54M | +16% y/y |
| Adjusted EPS · Q1-2026 | $0.10 | 0% y/y |
| Orders (excl. acquisitions) · Q1-2026 | $241M | +19% y/y |
| Orders (incl. acquisitions) · Q1-2026 | $288M | +42% y/y |
Guidance
FY26 revenue growth 22.0-24.0%; organic revenue growth 5.0-7.0%; Adjusted EBITDA $285-300M; Adjusted EBITDA margin 25.0-26.0%; Adjusted FCF $155-175M; Adjusted EPS $0.48-0.55 (previously $0.50-0.57)
Mirion reaffirmed most FY26 guidance, citing strong nuclear power demand and Paragon integration, with a slight downward revision to adjusted EPS due to a CEO retention grant.
Risks flagged
Adjusted EPS guidance revised down due to CEO retention grant.
“Adjusted EPS of approximately $0.48 – $0.55 per share (previously $0.50 – $0.57 per share); adjusted to reflect the impact of a special one-time CEO retention grant of performance vesting stock options disclosed on April 13, 2026.” · word for word
1 Apr 2026DEF 14AMirion filed its 2026 proxy statement (DEF 14A) detailing executive compensation, governance, and shareholder voting items.open
Figures in the filing · each found in the filing text
| Orders · FY2025 | $1.00B | +26% y/y |
| Revenue · FY2025 | $925M | +8% y/y |
| Net Income · FY2025 | $30M | |
| Adjusted EBITDA · FY2025 | $228M | +12% y/y |
| Nuclear & Safety Group Revenue · Nuclear & Safety · FY2025 | $615M | |
| Medical Group Revenue · Medical · FY2025 | $311M | |
| Net Cash Provided by Operating Activities · FY2025 | $143M | |
| Pro-forma Commercial Nuclear Power Revenue % · FY2025 | 47.0% |
Risks flagged
Integration risk from acquisitions
“In July, we acquired Certrec, and in December we closed on the acquisition of Paragon Energy Solutions.”
1 Apr 2026DEF 14AAnnual proxy statement disclosing executive compensation, governance, and business highlights for 2025.open
Figures in the filing · each found in the filing text
| Orders · FY2025 | $1.00B | +26% y/y |
| Revenue · FY2025 | $925M | +8% y/y |
| Net Income · FY2025 | $30M | |
| Adjusted EBITDA · FY2025 | $228M | +12% y/y |
| Nuclear Power Revenue Share (Pro-forma) · Nuclear & Safety · FY2025 | 47.0% | |
| Net Cash Provided by Operating Activities · FY2025 | $143M |
Risks flagged
Integration risk from acquisitions
“In July, we acquired Certrec, and in December we closed on the acquisition of Paragon Energy Solutions.” · word for word
19 Feb 202610-KRevenue $925M (+8% y/y); Net income (loss) $30M; Adjusted EBITDA $228M (+12% y/y); Guidance: Approximately 49% of remaining performance obligations expected to be recognized in 2026open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $925M | +8% y/y |
| Net income (loss) · FY2025 | $30M | |
| Adjusted EBITDA · FY2025 | $228M | +12% y/y |
| Remaining performance obligations · 2025-12-31 | $1.10B | +36% y/y |
| Nuclear & Safety segment revenue · Nuclear & Safety · FY2025 | $615M | |
| Medical segment revenue · Medical · FY2025 | $311M | |
| Nuclear & Safety segment Adjusted EBITDA · Nuclear & Safety · FY2025 | $178M | +11% y/y |
| Medical segment Adjusted EBITDA · Medical · FY2025 | $116M | +11% y/y |
| R&D expense · FY2025 | $39M | +11% y/y |
| Deferred contract revenue · 2025-12-31 | $112M | +16% y/y |
Guidance
Approximately 49% of remaining performance obligations expected to be recognized in 2026
Strong backlog growth, positive nuclear demand trends, and recent acquisitions position the company for continued growth.
Risks flagged
Integration risk from large acquisitions
“Acquired Paragon for $588.4M and Certrec for $82.9M in 2025; integration risks not quantified.”
Geopolitical and trade risk
“geopolitical and trade conditions, including matters affecting Russia, the relationship between the United States and China, conflict in the Middle East, risks related to tariffs” · word for word
Fixed-price contract risk
“Fixed-price contracts carry inherent risks, including risks of losses from underestimating costs, operational difficulties and other changes that may occur over the contract period.” · word for word
10 Feb 20268-K · 2.02Revenues $277M (+9% y/y); GAAP Net Income $18M (+12% y/y); Adjusted EBITDA $78M (+12% y/y); Guidance: Revenue growth 22-24%, organic growth 5-7%, adjusted EBITDA $285-300M, adjusted EPS $0.50-0.57earningsopen
Figures in the filing · each found in the filing text
| Revenues · Q4-2025 | $277M | +9% y/y |
| GAAP Net Income · Q4-2025 | $18M | +12% y/y |
| Adjusted EBITDA · Q4-2025 | $78M | +12% y/y |
| GAAP Net Earnings Per Share · Q4-2025 | $0.07 | 0% y/y |
| Adjusted Earnings Per Share · Q4-2025 | $0.15 | -12% y/y |
| Orders · FY2025 | $1.00B |
Guidance
Revenue growth 22-24%, organic growth 5-7%, adjusted EBITDA $285-300M, adjusted EPS $0.50-0.57
Strong guidance reflecting record orders, nuclear power tailwinds, and margin expansion.
Risks flagged
Guidance includes acquisition-related tailwinds; organic growth lower at 5-7%.
“Revenue growth of approximately 22.0% – 24.0%; includes a foreign exchange rate and acquisition-related tailwinds; Organic Revenue growth of approximately 5.0% – 7.0%” · word for word
8 Dec 20258-K · 1.01, 2.03Replacement Term Loans $450Mopen
Figures in the filing · each found in the filing text
| Replacement Term Loans | $450M |
Risks flagged
Refinancing risk; prepayment premium of 1% if repriced within six months.
“Prepayment premium of 1% if made subject to a repricing transaction within six months.” · word for word
29 Oct 202510-QMirion reported Q3 2025 revenue growth of 7.9% YoY, turned profitable, and announced significant M&A to expand nuclear power offerings.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $223M | +8% y/y |
| Net income (loss) · Q3-2025 | $3M | |
| Adjusted EBITDA · Q3-2025 | $52M | +15% y/y |
| Backlog · Q3-2025 | $808M | |
| Medical segment revenue · Medical · Q3-2025 | $79M | +6% y/y |
| Nuclear & Safety segment revenue · Nuclear & Safety · Q3-2025 | $145M | +9% y/y |
Risks flagged
Geopolitical risk (Russia-Ukraine)
“As of September 30, 2025, the Company has approximately $17.8 million in net contract assets and accounts receivable associated with Russian-related projects. The remaining performance obligations in our backlog for Russian-related projects was approximately $107.3 million at September 30, 2025.” · word for word
Integration risk from acquisitions
“The Paragon acquisition is expected to close before year-end 2025. Our ability to integrate, restructure, and leverage synergies of these businesses will impact our operating results over time.” · word for word
28 Oct 20258-K · 2.02Revenue $223M (+8% y/y); GAAP net income $3M; Adjusted EBITDA $52M (+15% y/y); Guidance: Adjusted Free Cash Flow guidance raised from $95-115M to $100-115M; other metrics reaffirmed.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $223M | +8% y/y |
| GAAP net income · Q3-2025 | $3M | |
| Adjusted EBITDA · Q3-2025 | $52M | +15% y/y |
| GAAP net earnings per share · Q3-2025 | $0.01 | |
| Adjusted earnings per share · Q3-2025 | $0.12 | +50% y/y |
Guidance
Adjusted Free Cash Flow guidance raised from $95-115M to $100-115M; other metrics reaffirmed.
Raised lower end of free cash flow guidance; reaffirmed revenue, EBITDA, EPS; strong demand in nuclear power.
Risks flagged
Tariff impacts on free cash flow; mitigating actions in place.
“revising Adjusted Free Cash Flow for the fiscal year... including estimated tariff impacts based on today’s levels, net of mitigating actions” · word for word
Timing risk on large opportunity pipeline; $110M pushed to 2026.
“$110 million of orders now expected to be awarded in 2026, due to timing.” · word for word
Mirion Technologies, Inc. — questions
- What did Mirion Technologies, Inc. file recently?
- 16 SEC filings in the last 12 months. Latest: 8-K on 2026-08-31 — Board approved new $250M share repurchase program through 2031; completed prior $100M program with $40M repurchases in Q3 2026.
Every figure on this page comes from Mirion Technologies, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.